Waters and University of Delaware Announce Bioprocessing Innovation Partnership, Plan 2022 Opening of Immerse Delaware Lab
Retrieved on:
Wednesday, October 20, 2021
University, Biotechnology, Education, Technology, Other Health, Health, Pharmaceutical, Other Science, Other Technology, Research, Science, 2013–14 Colonial Athletic Association men's basketball season, Engineering, Research, Carnegie Foundation for the Advancement of Teaching, Efficiency, University, University of Delaware, Mass spectrometry, Vaccine, Industry, Informatics, UD, Football, Colonial Athletic Association, Carnegie Foundation, Workforce, WAT, Partnership, Faculty, NYSE, STAR, Leadership, NCAA Division I Football Championship Subdivision alignment history, Technology, Glycosylation, Chromatography, Life, Food, CEO, Multimedia, Biomedical Advanced Research and Development Authority, National Institute, Solution, Health, Neutralizing antibody, LC-MS, Waters Corporation, Student, Fine chemical, Pharmaceutical industry, the University of Delaware, Waters Corporation, THE UNIVERSITY OF DELAWARE, WATERS CORPORATION
Key to this partnership is Immerse Delaware, an Innovation and Research Lab, (Immerse Delaware) set to open in early 2022 located at the University of Delaware Science, Technology and Advanced Research (STAR) campus.
Key Points:
- Key to this partnership is Immerse Delaware, an Innovation and Research Lab, (Immerse Delaware) set to open in early 2022 located at the University of Delaware Science, Technology and Advanced Research (STAR) campus.
- At Immerse Delaware, Waters will partner with students and faculty to identify and address the most significant challenges facing the biopharmaceutical industry.
- Immerse Delaware follows from our highly successful launch of Immerse Cambridge, A Waters Innovation and Research Lab, said Dr. Udit Batra, CEO and President of Waters Corporation.
- In addition to investing in Immerse Delaware, Waters has furthered its commitment to biopharmaceutical innovation by joining NIIMBL.